Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021May 12th 2021
Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.
Andreana N. Holowatyj, PhD, MS, Emphasizes the Complexity of Her Research in Colorectal Cancer and Future OpportunitiesMay 9th 2021
Holowatyj spoke about the molecular differences of early-onset colorectal cancer by race, while maintaining that race is a social construct, leading to a multitude of options for future research.
Andreana N. Holowatyj, PhD, MS, Details the Main Results of Research into Colorectal Cancer DisparitiesMay 8th 2021
The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.
Andreana N. Holowatyj, PhD, MS, Discusses Focal Questions Regarding Colorectal Cancer DisparitiesMay 5th 2021
Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.
First-line Pembrolizumab Monotherapy Improves HRQOL Versus Chemotherapy for Metastatic Colorectal CancerMay 3rd 2021
A phase 3 trial found that pembrolizumab for patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer significantly improved health-related quality of life compared with chemotherapy.
Andreana N. Holowatyj, PhD, MS, on Rising Rates of Early-Onset Colorectal Cancer WorldwideApril 30th 2021
The lead author spoke about the rising incidence of early-onset colorectal cancer, which was the focal point of her research presented at the American Association for Cancer Research Annual Meeting 2021.
Complete Mesocolic Excision is a Safe Option in Laparoscopic Right HemicolectomyApril 7th 2021
Early safety data from the RELARC trial showed complete mesocolic excision doesn’t increase intraoperative and postoperative complications of laparoscopic right hemicolectomy compared with D2 dissection when done by an experienced surgeon.
Photoacoustic Microscopy With Ultrasound Technology Is Feasible for Sensing Residual Rectal Tumors Following SurgeryApril 2nd 2021
A new imaging technique that pairs acoustic resolution photoacoustic microscopy co-registered with ultrasound and an artificial intelligence neural network was proven feasible for use in detecting residual tumor tissue in patients with rectal cancer.
KRAS Mutations in Unresectable Colorectal Liver Metastases Linked to Reduced Response RatesMarch 18th 2021
Based on a single-institution study, investigators were able to correlate outcomes for unresectable colorectal liver metastases with the addition of hepatic arterial infusion pump therapy to systemic therapy to the presence of a mutation in KRAS.
Study Identifies Associations Between Low CRC Risk and Prudent Dietary PatternsMarch 1st 2021
“Emerging evidence supports a possible role for overall dietary patterns that, in totality, emphasize habitually consuming fruits, vegetables, grains, and low-fat dairy and reducing red meat and alcohol intake,” wrote the study authors.
Aspirin Use Beginning Before and Continuing After Age 70 Reduces Risk of CRCFebruary 16th 2021
A pooled analysis of 2 cohort studies suggested that individuals who began using aspirin before age 70 years and continued using the agent later in life had a reduced risk of colorectal cancer.
Study Suggests Oxaliplatin-Fluoropyrimidine Combo To Be Standard-of-Care Adjuvant Treatment for Stage III MSI/dMMR Colon CancerFebruary 4th 2021
“As the current work is the largest ever published on adjuvant [fluoropyrimidine; FP] for patients with MSI stage III [colon cancer], it suggests that FP alone should not be recommended as adjuvant treatment for these patients,” wrote the study authors, who were led by Romain Cohen, MD, PhD.
TAS-102 Plus Bevacizumab Leads to Improved OS in Patients With mCRC Ineligible for Intensive TherapyJanuary 17th 2021
When compared with standard capecitabine and bevacizumab therapy, patients with unresectable metastatic colorectal cancer saw an increase in overall and progression-free survival.
Targeted Intervention Necessary for Low Health-Related Quality of Life Scores in Young Survivors of Colorectal CancerJanuary 16th 2021
Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life among younger survivors of colorectal cancer is poor and social and functional well-being are also suffering as treatment durations increase.
Patients With MSI-H/dMMR mCRC Saw Improvement in PFS, HRQoL with Pembrolizumab MonotherapyJanuary 16th 2021
When compared with chemotherapy, patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer saw significant improvement in progression-free survival with the frontline use of pembrolizumab monotherapy, while demonstrating superior safety.
Pembrolizumab Plus Capecitabine and Bevacizumab Tolerable in Patients with MSS mCRCJanuary 15th 2021
The phase 2 study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium reported a total of 2 responses at the interim analysis, meeting criteria to continue accrual.
Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 TrialJanuary 15th 2021
SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.
SWOG S1406 Finds Vemurafenib Combo With Irinotecan, Cetuximab Effective for BRAF-Mutatant CRCJanuary 12th 2021
The study assessed the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E–mutated metastatic CRC who had been previously treated with 1 or 2 regimens.
Predictive Model Able to Predict Colorectal Cancer Risk Among Average-Risk PersonsDecember 21st 2020
This new risk estimation model could help physicians determine whether an average risk patient’s specific risk indicates an at-home stool test would be a good screening option or suggests a colonoscopy may be the most appropriate option.
USMSTF Releases New Guidelines on Management of Malignant Colorectal PolypsDecember 2nd 2020
The guidance is intended to inform gastroenterologists of how to assess lesions for endoscopic features associated with cancer, discuss how these factors guide endoscopic management, and to outline the factors that frame whether to advise surgery after a malignant polyp has been endoscopically resected.
Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid TumorsNovember 24th 2020
Adagrasib demonstrated an acceptable safety profile and promising clinical activity in pretreated patients with non-small cell lung cancer, colorectal cancer, and other solid tumors with a KRAS G12C mutation.